Developer docs
API playgroundTry for free, no card

Search company profiles

Aytu BioPharma

Full company profile

uuid0000zpq

Namestring
Aytu BioPharma
Legal namestring
Aytu BioPharma, Inc.
Websiteurl
aytubio.com
Company typeenum
Public
Founded yearint
2000
Descriptiontext

Aytu BioPharma is a specialty pharmaceutical company focused on central nervous system (CNS) therapeutics, serving patients with major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), and pediatric allergic and fluoride-deficiency conditions. The company's flagship asset is EXXUA (gepirone), a first-in-class selective serotonin 5HT1a receptor agonist FDA-approved in September 2024 and commercially launched in mid-December 2025 to address the over $22 billion U.S. prescription MDD market. EXXUA is protected by a method-of-use patent extending through September 2030, and the company completed full field sales force deployment in mid-January 2026 to drive adoption.

The company's commercial portfolio also includes the ADHD franchise (Adzenys XR-ODT, Cotempla XR-ODT, METADATE CD) acquired via the 2021 merger with Neos Therapeutics, plus a legacy pediatric portfolio (Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor). Distribution is supported by Aytu RxConnect, a patient access program operating through approximately 1,000 pharmacies nationwide that reduces out-of-pocket costs and improves adherence. International ADHD rights are out-licensed to Medomie Pharma (Israel/Palestinian Authority) and Lupin Pharma Canada.

Aytu generates revenue primarily through prescription pharmaceutical product sales in the United States, supplemented by international licensing royalties. Q3 FY2026 net revenue was $12.4 million, with quarterly revenues of $13.9M (Q1) and $15.2M (Q2) indicating a transitional period as legacy ADHD declines under generic competition and EXXUA ramps. The company has reported 11 consecutive quarters of positive adjusted EBITDA excluding EXXUA launch investments, holds $30.0 million in cash as of December 31, 2025, and is publicly traded on NASDAQ under ticker AYTU, with stockholders' equity of $35.1 million following an April 2026 warrant reclassification.

Short descriptiontext

Aytu BioPharma is a specialty pharmaceutical company developing and commercializing central nervous system therapeutics, including EXXUA for major depressive disorder and an ADHD franchise, serving patients in the U.S. through a specialty field sales force and a 1,000-pharmacy patient access network.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersDenver, United States
HQ citystring
Denver
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
specialty pharmaceuticals, CNS therapeutics, depression treatment drugs, ADHD medications, patient access programs
Industry2 codes
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAKAG
Patient Access Programs & Affordability (Copay/Hubs/PSP)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing
NAICS code1 code
  • Pharmacies and Drug Retailers456110
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (CNS Therapeutics)
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Pharmaceutical product sales
TypeOne Time License
Description

Revenue generated from sales of proprietary pharmaceutical products including EXXUA for MDD, ADHD treatments (Adzenys XR-ODT, Cotempla XR-ODT, METADATE CD), pediatric products (Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor). Products are sold through prescription-based distribution channels.

stocktitan.net
2Licensing revenue
TypeLicensing Royalties
Description

Out-licensing of ADHD brands to partners in markets outside the United States, including Medomie Pharma (Israel and Palestinian Authority) and Lupin Pharma Canada.

aytubio.com
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 8 records shown
1EXXUA
Description

First-in-class medication approved by FDA for treating major depressive disorder in adults; a selective serotonin 5HT1a receptor agonist

aytubio.com
+7 more records
Core offering1 text field

Aytu BioPharma develops, manufactures, and commercializes FDA-approved prescription central nervous system (CNS) pharmaceuticals, anchored by EXXUA (gepirone), a first-in-class 5HT1a receptor agonist for major depressive disorder, and a portfolio of extended-release ADHD stimulants (Adzenys XR-ODT, Cotempla XR-ODT, Metadate CD). The company also markets a legacy pediatric portfolio (Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor) and operates the Aytu RxConnect patient access program connecting patients to approximately 1,000 pharmacies nationwide.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Over 1,300 prescriptions written by more than 450 unique prescribers within initial EXXUA launch period
+2 more records
Product overview1 text field

Aytu BioPharma is a specialty pharmaceutical company with a portfolio of central nervous system (CNS) products organized into three main categories: (1) EXXUA, a first-in-class FDA-approved treatment for major depressive disorder launched in December 2025; (2) an ADHD Portfolio comprising ADZENYS XR-ODT, COTEMPLA XR-ODT, and METADATE CD, which are CNS stimulants for ADHD patients across different age groups; and (3) a legacy Pediatric Portfolio including Karbinal ER for allergic conditions and Poly-Vi-Flor/Tri-Vi-Flor for fluoride deficiency. The company also operates Aytu RxConnect, a patient access program that provides affordable access to its products through approximately 1,000 pharmacies nationwide.

Product and service8 records
1EXXUA™ (gepirone) extended-release tablets
CategoryCentral Nervous System (CNS) Therapeutics — Antidepressant
Description

First-in-class FDA-approved selective serotonin 5HT1a receptor agonist for the treatment of major depressive disorder (MDD) in adults; gepirone extended-release tablet.

2ADZENYS XR-ODT®
CategoryCentral Nervous System (CNS) Therapeutics — ADHD Stimulant
Description

Central nervous system (amphetamine) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older; extended-release orally disintegrating tablet.

3COTEMPLA XR-ODT®
CategoryCentral Nervous System (CNS) Therapeutics — ADHD Stimulant
Description

Central nervous system (methylphenidate) stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; extended-release orally disintegrating tablet.

4METADATE® CD
CategoryCentral Nervous System (CNS) Therapeutics — ADHD Stimulant
Description

Central nervous system (methylphenidate) stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age; extended-release capsule.

5Karbinal™ ER
CategoryPediatric Allergy Therapeutics
Description

Prescription medication indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, and other common allergic conditions.

6Poly-Vi-Flor®
CategoryPediatric Nutritional Supplements
Description

Prescription fluoride-based supplement product line containing combinations of vitamins and fluoride in various oral formulations, prescribed for infants and children to treat or prevent fluoride deficiency.

7Tri-Vi-Flor®
CategoryPediatric Nutritional Supplements
Description

Complementary prescription fluoride-based supplement product line containing combinations of vitamins and fluoride in various oral formulations, prescribed for infants and children to treat or prevent fluoride deficiency.

8Aytu RxConnect
CategoryPatient Access / Affordability Program
Description

Patient access program that enables affordable, predictable patient access to Aytu's portfolio of products through approximately 1,000 pharmacies nationwide, supporting patients through their complex treatment journey.

Scale indicator10 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Licensed rights to Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) to commercialize these ADHD products in Israel and the Palestinian Authority.

Strategic tierMinorTypeChannel Partner/ Reseller/ Distributor
Description

Licensed rights to Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) to commercialize these ADHD products in Canada.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Commercial-stage CNS specialty pharma with Auvelity, an FDA-approved novel-mechanism treatment for MDD. Directly comparable to Aytu given similar size, MDD focus, and novel-mechanism strategy targeting the same prescriber base.

TypeDirect peer
Description

CNS-focused specialty pharma with FDA-approved treatments for major depressive disorder (Zurzuvae) and postpartum depression. Directly comparable given overlapping MDD therapeutic area and similar specialty pharma commercial model.

TypeDirect peer
Description

Specialty pharma focused on CNS disorders including ADHD and epilepsy. Directly comparable product overlap in ADHD (Qelbree) and similar specialty pharma commercial model targeting psychiatrists and pediatricians.

TypeDirect peer
Description

Specialty pharma commercializing Korlym for Cushing's syndrome with pipeline in psychiatry. Comparable small-cap CNS-focused commercial model with single-asset revenue concentration and similar prescriber targeting.

TypeDirect peer
Description

Specialty pharma commercializing Caplyta for schizophrenia and bipolar depression. Directly comparable given CNS focus, novel-mechanism therapies, and overlap in depression/psychiatry prescriber base.

TypeDirect peer
Description

CNS specialty pharma commercializing Nuplazid for Parkinson's disease psychosis with growing psychiatry franchise. Comparable mid-cap CNS specialty commercial model targeting overlapping physician specialties.

TypeBroad incumbent
Description

Specialty pharma with generics, brands, and rare disease portfolio. Comparable as a small-cap specialty pharma with mixed legacy and growth franchises, though broader therapeutic focus than Aytu.

TypeBroad incumbent
Description

Large specialty pharma with significant CNS franchise (Xywav, Epidiolex, Sunosi). Comparable CNS commercial infrastructure and target prescriber base, though much larger scale and broader portfolio than Aytu.

TypeEmerging player
Description

Private specialty pharma with ADHD and CNS pipeline including novel extended-release stimulant formulations. Comparable as a niche CNS/ADHD-focused company, though privately held and pre-IPO relative to Aytu.

TypeEmerging player
Description

CNS-focused biotech with pipeline in schizophrenia, Parkinson's, and epilepsy. Comparable CNS therapeutic focus and novel-mechanism strategy, though still in earlier commercial stages than Aytu.

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks1 record

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A3 records

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Aytu BioPharma

Specialty Pharmaceuticals (CNS Therapeutics)aytubio.com

Aytu BioPharma is a specialty pharmaceutical company developing and commercializing central nervous system therapeutics, including EXXUA for major depressive disorder and an ADHD franchise, serving patients in the U.S. through a specialty field sales force and a 1,000-pharmacy patient access network.

What Aytu BioPharma does

Aytu BioPharma is a specialty pharmaceutical company focused on central nervous system (CNS) therapeutics, serving patients with major depressive disorder (MDD), attention deficit hyperactivity disorder (ADHD), and pediatric allergic and fluoride-deficiency conditions. The company's flagship asset is EXXUA (gepirone), a first-in-class selective serotonin 5HT1a receptor agonist FDA-approved in September 2024 and commercially launched in mid-December 2025 to address the over $22 billion U.S. prescription MDD market. EXXUA is protected by a method-of-use patent extending through September 2030, and the company completed full field sales force deployment in mid-January 2026 to drive adoption.

The company's commercial portfolio also includes the ADHD franchise (Adzenys XR-ODT, Cotempla XR-ODT, METADATE CD) acquired via the 2021 merger with Neos Therapeutics, plus a legacy pediatric portfolio (Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor). Distribution is supported by Aytu RxConnect, a patient access program operating through approximately 1,000 pharmacies nationwide that reduces out-of-pocket costs and improves adherence. International ADHD rights are out-licensed to Medomie Pharma (Israel/Palestinian Authority) and Lupin Pharma Canada.

Aytu generates revenue primarily through prescription pharmaceutical product sales in the United States, supplemented by international licensing royalties. Q3 FY2026 net revenue was $12.4 million, with quarterly revenues of $13.9M (Q1) and $15.2M (Q2) indicating a transitional period as legacy ADHD declines under generic competition and EXXUA ramps. The company has reported 11 consecutive quarters of positive adjusted EBITDA excluding EXXUA launch investments, holds $30.0 million in cash as of December 31, 2025, and is publicly traded on NASDAQ under ticker AYTU, with stockholders' equity of $35.1 million following an April 2026 warrant reclassification.

Aytu BioPharma firmographics

Firmographics
Name
Aytu BioPharma
Legal name
Aytu BioPharma, Inc.
Website
https://aytubio.com
Company type
Public
Founded year
2000
Operating status
Operating
Headcount range
51–100 employees
Short description
Aytu BioPharma is a specialty pharmaceutical company developing and commercializing central nervous system therapeutics, including EXXUA for major depressive disorder and an ADHD franchise, serving patients in the U.S. through a specialty field sales force and a 1,000-pharmacy patient access network.
Ownership category
akta.pro rank

Aytu BioPharma industry classification

Industry
Product category
Specialty Pharmaceuticals (CNS Therapeutics)
NAICS
Pharmacies and Drug Retailers (456110)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIACAC
Neurology & CNS Specialty Pharmaceuticals
SECONDARYHLAIAKAG
Patient Access Programs & Affordability (Copay/Hubs/PSP)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Market Access and Pricing

Keywords

  • Specialty pharmaceuticals
  • CNS therapeutics
  • Depression treatment drugs
  • ADHD medications
  • Patient access programs

Where Aytu BioPharma is headquartered

Location

Headquarters

HQ city
Denver
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Aytu BioPharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Operations, Personnel, Marketing or Sales, Technology or R&D, Supply Chain

Revenue model

  1. Pharmaceutical product sales: Revenue generated from sales of proprietary pharmaceutical products including EXXUA for MDD, ADHD treatments (Adzenys XR-ODT, Cotempla XR-ODT, METADATE CD), pediatric products (Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor). Products are sold through prescription-based distribution channels.
  2. Licensing revenue: Out-licensing of ADHD brands to partners in markets outside the United States, including Medomie Pharma (Israel and Palestinian Authority) and Lupin Pharma Canada.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Aytu BioPharma product offering

Product offering

Core offering

Aytu BioPharma develops, manufactures, and commercializes FDA-approved prescription central nervous system (CNS) pharmaceuticals, anchored by EXXUA (gepirone), a first-in-class 5HT1a receptor agonist for major depressive disorder, and a portfolio of extended-release ADHD stimulants (Adzenys XR-ODT, Cotempla XR-ODT, Metadate CD). The company also markets a legacy pediatric portfolio (Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor) and operates the Aytu RxConnect patient access program connecting patients to approximately 1,000 pharmacies nationwide.

Product overview

Aytu BioPharma is a specialty pharmaceutical company with a portfolio of central nervous system (CNS) products organized into three main categories: (1) EXXUA, a first-in-class FDA-approved treatment for major depressive disorder launched in December 2025; (2) an ADHD Portfolio comprising ADZENYS XR-ODT, COTEMPLA XR-ODT, and METADATE CD, which are CNS stimulants for ADHD patients across different age groups; and (3) a legacy Pediatric Portfolio including Karbinal ER for allergic conditions and Poly-Vi-Flor/Tri-Vi-Flor for fluoride deficiency. The company also operates Aytu RxConnect, a patient access program that provides affordable access to its products through approximately 1,000 pharmacies nationwide.

Differentiator

Problem solved

Functional benefit

Brands

  • EXXUA: First-in-class medication approved by FDA for treating major depressive disorder in adults; a selective serotonin 5HT1a receptor agonist
  • Adzenys XR-ODT
  • Cotempla XR-ODT
  • Metadate CD
  • Aytu RxConnect
  • Karbinal ER
  • Poly-Vi-Flor
  • Tri-Vi-Flor

Products and services

  • EXXUA™ (gepirone) extended-release tablets First-in-class FDA-approved selective serotonin 5HT1a receptor agonist for the treatment of major depressive disorder (MDD) in adults; gepirone extended-release tablet.
  • ADZENYS XR-ODT® Central nervous system (amphetamine) stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients 6 years and older; extended-release orally disintegrating tablet.
  • COTEMPLA XR-ODT® Central nervous system (methylphenidate) stimulant indicated for the treatment of ADHD in patients 6 to 17 years of age; extended-release orally disintegrating tablet.
  • METADATE® CD Central nervous system (methylphenidate) stimulant indicated for the treatment of ADHD in patients 6 to 15 years of age; extended-release capsule.
  • Karbinal™ ER Prescription medication indicated to treat various allergic conditions including seasonal and perennial allergic rhinitis, vasomotor rhinitis, and other common allergic conditions.
  • Poly-Vi-Flor® Prescription fluoride-based supplement product line containing combinations of vitamins and fluoride in various oral formulations, prescribed for infants and children to treat or prevent fluoride deficiency.
  • Tri-Vi-Flor® Complementary prescription fluoride-based supplement product line containing combinations of vitamins and fluoride in various oral formulations, prescribed for infants and children to treat or prevent fluoride deficiency.
  • Aytu RxConnect Patient access program that enables affordable, predictable patient access to Aytu's portfolio of products through approximately 1,000 pharmacies nationwide, supporting patients through their complex treatment journey.

Quantifiable outcome

  • Over 1,300 prescriptions written by more than 450 unique prescribers within initial EXXUA launch period
  • +2 more outcomes

Companies that use Aytu BioPharma

Customer profile

Segments3 records

Ideal customer profiles3 records

Aytu BioPharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

Aytu BioPharma partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered minor.

  • Medomie PharmaminorChannel Partner/ Reseller/ DistributorLicensed rights to Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) to commercialize these ADHD products in Israel and the Palestinian Authority.
  • Lupin Pharma CanadaminorChannel Partner/ Reseller/ DistributorLicensed rights to Adzenys XR-ODT (amphetamine) and Cotempla XR-ODT (methylphenidate) to commercialize these ADHD products in Canada.

Scale indicators10 records

Recent moves6 records

Expansion highlights5 records

Aytu BioPharma competitors and assessment

Company assessment

Direct peers

  • Axsome Therapeutics: Commercial-stage CNS specialty pharma with Auvelity, an FDA-approved novel-mechanism treatment for MDD. Directly comparable to Aytu given similar size, MDD focus, and novel-mechanism strategy targeting the same prescriber base.
  • Sage Therapeutics: CNS-focused specialty pharma with FDA-approved treatments for major depressive disorder (Zurzuvae) and postpartum depression. Directly comparable given overlapping MDD therapeutic area and similar specialty pharma commercial model.
  • Supernus Pharmaceuticals: Specialty pharma focused on CNS disorders including ADHD and epilepsy. Directly comparable product overlap in ADHD (Qelbree) and similar specialty pharma commercial model targeting psychiatrists and pediatricians.
  • Corcept Therapeutics: Specialty pharma commercializing Korlym for Cushing's syndrome with pipeline in psychiatry. Comparable small-cap CNS-focused commercial model with single-asset revenue concentration and similar prescriber targeting.
  • Intra-Cellular Therapies: Specialty pharma commercializing Caplyta for schizophrenia and bipolar depression. Directly comparable given CNS focus, novel-mechanism therapies, and overlap in depression/psychiatry prescriber base.
  • Acadia Pharmaceuticals: CNS specialty pharma commercializing Nuplazid for Parkinson's disease psychosis with growing psychiatry franchise. Comparable mid-cap CNS specialty commercial model targeting overlapping physician specialties.

Broad incumbents

  • ANI Pharmaceuticals: Specialty pharma with generics, brands, and rare disease portfolio. Comparable as a small-cap specialty pharma with mixed legacy and growth franchises, though broader therapeutic focus than Aytu.
  • Jazz Pharmaceuticals: Large specialty pharma with significant CNS franchise (Xywav, Epidiolex, Sunosi). Comparable CNS commercial infrastructure and target prescriber base, though much larger scale and broader portfolio than Aytu.

Emerging players

  • Tris Pharma: Private specialty pharma with ADHD and CNS pipeline including novel extended-release stimulant formulations. Comparable as a niche CNS/ADHD-focused company, though privately held and pre-IPO relative to Aytu.
  • Cerevel Therapeutics: CNS-focused biotech with pipeline in schizophrenia, Parkinson's, and epilepsy. Comparable CNS therapeutic focus and novel-mechanism strategy, though still in earlier commercial stages than Aytu.

Market position

Competitive moat4 records

Key risks1 record

Key highlights7 records

Customer concentration

Aytu BioPharma social profiles

Digital presence

Aytu BioPharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Aytu BioPharma leadership team

Management profile

Number of profiles

Profiles11 records

Aytu BioPharma subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Aytu BioPharma funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Aytu BioPharma M&A and investment

M&A and investment

M&A3 records

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Aytu BioPharma

What does Aytu BioPharma do?

Aytu BioPharma develops, manufactures, and commercializes FDA-approved prescription central nervous system (CNS) pharmaceuticals, anchored by EXXUA (gepirone), a first-in-class 5HT1a receptor agonist for major depressive disorder, and a portfolio of extended-release ADHD stimulants (Adzenys XR-ODT, Cotempla XR-ODT, Metadate CD). The company also markets a legacy pediatric portfolio (Karbinal ER, Poly-Vi-Flor, Tri-Vi-Flor) and operates the Aytu RxConnect patient access program connecting patients to approximately 1,000 pharmacies nationwide.

Is Aytu BioPharma a public or private company?

Aytu BioPharma is a public company. It is classified as public and is currently operating.

When was Aytu BioPharma founded?

Aytu BioPharma was founded in 2000. It employs 51 to 100 people.

Where is Aytu BioPharma based?

Aytu BioPharma is headquartered in Denver, United States, in the North America region.

How does Aytu BioPharma make money?

Two revenue lines are on record. Pharmaceutical product sales are the primary driver. The others are licensing revenue.

Who are Aytu BioPharma's main competitors?

Direct peers on record are Axsome Therapeutics, Sage Therapeutics, Supernus Pharmaceuticals, Corcept Therapeutics, Intra-Cellular Therapies and Acadia Pharmaceuticals. Broad incumbents are ANI Pharmaceuticals and Jazz Pharmaceuticals. Emerging players are Tris Pharma and Cerevel Therapeutics.

Does Aytu BioPharma have an API?

No public API is recorded for Aytu BioPharma.

What industry is Aytu BioPharma in?

Aytu BioPharma's product category is Specialty Pharmaceuticals (CNS Therapeutics). Its primary akta.pro industry code is HLAIACAC, Neurology & CNS Specialty Pharmaceuticals, with a secondary code of HLAIAKAG, Patient Access Programs & Affordability (Copay/Hubs/PSP). Its NAICS code is 456110 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR Newswire$HAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Aytu BioPharma, Inc. (NASDAQ: AYTU)Monteverde & Associates PC is investigating Aytu BioPharma's proposed sale to Rosemont Pharmaceuticals Holdings, with shareholders expected to receive $2.70 in cash per share. The firm, a class action securities firm, is seeking shareholder concerns and additional information.Defense WorldAytu BioPharma (NASDAQ:AYTU) Downgraded by Lake Street Capital to “Hold”Lake Street Capital downgraded Aytu BioPharma from Buy to Hold with a $2.70 price target. The company reported a Q1 loss of $0.20 per share, beating the $0.26 consensus, with revenue of $14.84 million. Analysts have a consensus Hold rating and $8.60 target price.Investing.comWhy is Aytu BioPharma stock surging today?Aytu BioPharma stock surged nearly 45.9% to $2.655 after Rosemont Pharmaceuticals agreed to acquire it for $2.70 per share in an all-cash tender offer, valued at about $56 million. The deal, a 41.1% premium, was approved by Aytu's board and expected to close by end of 2026. Aytu also reported Q1 revenue of $14.84 million, beating estimates.Business & FinancialBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors Of The Following Investigations: Aytu Biopharma, Inc. (Nasdaq AYTU), Rapid Micro Biosystems, Inc. (Nasdaq RPID), Advantage Energy Ltd. (OTC AAVVF), Canaccord Genuity Group Inc. (OTC CCORF)Brodsky & Smith notified investors of investigations into four companies' merger processes, including Aytu Biopharma, Rapid Micro Biosystems, Advantage Energy, and Canaccord Genuity. The investigations examine whether boards breached fiduciary duties by failing to conduct fair processes and pay fair value. Specific acquisition prices are disclosed for each deal.FinancialContent Business PageBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTCBrodsky & Smith notified investors of four shareholder investigations into merger transactions. The cases involve Aytu BioPharma, Rapid Micro Biosystems, Advantage Energy, and Canaccord Genuity, each with specific acquisition prices and fiduciary duty questions. No cost or financial obligation is stated for investors.GlobeNewswireBRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Aytu BioPharma, Inc. (Nasdaq – AYTU), Rapid Micro Biosystems, Inc. (Nasdaq – RPID), Advantage Energy Ltd. (OTC – AAVVF), Canaccord Genuity Group Inc. (OTC – CCORF)Brodsky & Smith notified investors of investigations into four companies: Aytu BioPharma, Rapid Micro Biosystems, Advantage Energy, and Canaccord Genuity. The investigations question whether each company's board breached fiduciary duties by failing to conduct a fair process in their respective mergers, including whether the transactions pay fair value to shareholders.Business & FinancialAYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.Ademi LLP is investigating whether the proposed acquisition of Aytu Biopharma by Rosemont Pharmaceuticals provides fair value to public shareholders and whether the board adequately protected their interests. The investigation covers purchase price, change-of-control benefits, restrictions on competing transactions, and board conduct.GlobeNewswireAYTU Shareholder Alert: Ademi LLP Investigates Whether Buyout Fairly Values Aytu Biopharma, Inc.Ademi LLP is investigating whether Rosemont Pharmaceuticals' acquisition of Aytu Biopharma provides fair value to public shareholders. The firm notes shareholders would receive $2.70 per share in the tender offer and is examining change-of-control benefits, competing offer restrictions, and board conduct.The Pharma LetterAytu BioPharma leaps on news of acquisition by Rosemont for $2.70 per shareAytu BioPharma announced a definitive merger agreement with Rosemont Pharmaceuticals, with Rosemont to acquire Aytu for $2.70 per share. The tender offer is subject to customary conditions, including a majority tender of shares and warrant exercise or termination. The deal represents about $56 million in fully diluted equity value.The future of tradingAytu Biopharma Inc reports results for the quarter ended September 30 - Earnings SummaryAytu Biopharma reported a quarterly adjusted loss of 20 cents per share for the quarter ended September 30, beating the analyst mean of 26 cents. Revenue rose 6.9% to $14.84 million, and the company's shares fell 31.5% year-to-date.